chemieunternehmen.com

 Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-biologics-start-next-project-on-the-cbl-b-target-5028

Evotec AG today announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/second-multi-target-collaboration-with-ucb-announced-5026

Evotec AG today announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/acquisition-of-remaining–30-of-indian-joint-venture-from-dil-5024

Evotec AG and Roche AG announced today that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-roche-agree-to-develop-compound-that-could-slow-the-progression-of-alzheimers-disease-5022

Evotec AG  today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/pre-clinical–milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-received-5020

Evotec AG today reported financial results and corporate updates for the first half of 2011. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-34-revenue-and-profitable-earnings-growth-revenue-guidance-raised-5018

Evotec AG today announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/p2x7-antagonist-programme-evt-401-to-a-top-tier-global-animal-health-company-partnered-5016

Evotec AG today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/multi-target-collaboration-with-ucb-in-neurodegenerative-and-neurological-diseases-announced-5012

Evotec AG today announced the achievement of specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. and the receipt of a milestone payment.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/milestone-in-an-ion-channel-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-achieved-5010